NCT00998010 - Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 3, 2011

Primary Completion Date

March 29, 2016

Study Completion Date

April 20, 2018

Conditions

Brain and Central Nervous System Tumors

Interventions

DRUG

bortezomib + temozolomide+ radiation therapy

Patients will be treated with Bortezomib at 1.3 mg/m2 IV on days1,4,8,11,29,32,36 and 39 and Temozolomide on 75mg/m2 daily during radiation. External beam fractionated regional radiation will be given on consecutive week days at 200 centigray (cGy) daily doses to a total dose of 6000 cGy.

Trial Locations (1)

90095

University of California Los Angeles, Los Angeles